Inspyr Therapeutics, Inc.
http://www.inspyrtx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Inspyr Therapeutics, Inc.
Appointments: Oculis, PellePharm, Syntimmune, Sterna Biologicals, Proclara Biosciences, Denovo Biopharma and OrphoMed
The latest biopharma industry appointments include new CEOs at Oculis, PellePharm, Syntimmune and Sterna Biologicals and a new CFO at Oculis, as well as new CMOs at Proclara Biosciences, Denovo Biopharma and OrphoMed.
Tech Transfer Roundup: Busy Inspyr Collaborates With Virginia, NYU
University researchers will examine adenosine receptor modulator technology’s potential in C. difficile infection and atherosclerosis. CRISPR Therapeutics is partnering with University of Alabama-Birmingham to evaluate gene-editing procedures in Friedreich’s ataxia.
Appointments: CRISPR, KSQ Therapeutics, Immunocore, Cellectis, Translate Bio and biOasis
This week's roundup includes CEO appointments by CRISPR Therapeutics and KSQ Therapeutics, in addition to various other board and high-level appointments by Oncorus, Cellectis, BiOasis, Avillion and Revolution Medicines.
Finance Watch: Raising Cash Before A Trump Slump, La Jolla Nabs $125m, Akcea Eyes $100m IPO
La Jolla Pharmaceutical grossed $125m, Inspyr Therapeutics signs a deal to raise up to $100m, Ionis's Akcea makes $100m IPO plans, and $64m in cash for SutroVax tops recent venture capital rounds.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Drug Delivery
- Site Specific
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
-
- GenSpera, Inc.
- Lewis and Clark Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice